周三早盘,Penumbra 公司股价出现8.14%的大涨幅度,引发了投资者的广泛关注。
财报数据显示,该医疗器械公司第四季度营收同比增长10.8%至3.15亿美元,超过了分析师此前3.12亿美元的预期。公司近年来在多个利基领域取得积累,深受市场看好。
财报公布后,多家分析机构上调了该股目标价,看好公司未来表现。摩根大通分析师认为,Penumbra公司今年的销售额将继续保持适度增长,利润率也将大幅提高,基本业务表现良好。目标价由230美元上调至285美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.